AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal
AbbVie Targets Psychedelic-Based Depression Drug Market With $1.2 Billion Deal Summary AbbVie has agreed to purchase an experimental depression drug from Gilgamesh Pharmaceuticals for up to $1.2 billion, moving the…
